Labcorp Holdings Inc. (NYSE: LH) announced on August 10, 2026 that the U.S. Food and Drug Administration has approved PGDx elio tissue complete CDx as a companion diagnostic for identifying melanoma patients whose tumors carry BRAF V600E or BRAF V600K mutations and who may benefit from FDA-approved BRAF inhibitors or approved BRAF and MEK inhibitor
Senhwa Biosciences has secured Taiwan regulatory clearance for a multicenter Phase 1b/2a trial combining pidnarulex, or CX-5461, with BeOne Medicines’ PD-1 inhibitor tislelizumab in advanced solid tumors. The study will test whether DNA replication stress can make immunologically cold or checkpoint-resistant cancers more responsive to immunotherapy.
Obsidian Therapeutics closes its Galera merger and $350 million financing, putting OBX-115 melanoma data and execution under investor scrutiny.
Discover how Orion and Shilpa Medicare’s nivolumab biosimilar deal could reshape European oncology access, pricing and hospital procurement.
Find out how DermaSensor’s CE Mark and NHS study could reshape AI-assisted skin cancer assessment across European primary care.
Obsidian Therapeutics will present OBX-115 melanoma data at ASCO 2026. Read why the update matters for TIL therapy, scalability, and solid tumor strategy.
Aulos Bioscience will present new imneskibart melanoma data at ASCO 2026. Read what it could mean for IL-2 therapy and immuno-oncology.